Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEYOND: Bevacizumab in Advanced Non-Squamous NSCLC
NCT01364012Phase 3Completed
- Sponsor
- Roche
- Start
- May 2011
- Primary completion
- Jan 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) comparing Bevacizumab + Paclitaxel/Carboplatin with Placebo + Paclitaxel/Carboplatin (2 arms). Primary endpoint: Progression-Free Survival at 20 months. Started May 2011; status: completed.
02
Drugs
bevacizumab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT01364012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01364012.